Investigational Product/ Process /Intervention
Research Description/ Research Lay Summary
Anaemia is often prevalent among renal failure patients and as the cost of treatment is high, this warrants an economic analysis on the subject. The cost viewpoint taken here is that of MOH and the main outcome of interest is quality adjusted life years on dialysis for patients receiving erythropoietin (EPO)
Research Keyword
cost effective analysis
cost per life years saved
Quality adjusted life years
erythropoietin
renal failure
dialysis
Research Objective
To determine the cost effectiveness of EPO therapy in the MOH dialysis program.
Inclusion & Exclusion Criteria
Inclusion Criteria
Nephrology medical professionals (nephrologists, nurses or medical assistants)
Patients receiving dialysis
Exclusion Criteria
Nephrology medical professionals (nephrologists, nurses or medical assistants)
Patients receiving dialysis
Expected / Actual Date Study Starts - First Enrolment of subject / Collecting data
Nov, 30 2004
Expected / Actual Date Study Completed
Feb, 28 2006
Expected / Actual Duration of Study Enrollment / Data Collection
65 weeks
Subject (Sample Size) Description
Age Range :
Gender :
Biospecimen Collection & Archiving
-
Current Study Status
Completed
Principal Investigator Information
Datin Dr Faridah Aryani Md. Yusof
Pharmaceutical Services Division, MOH
Sponsor
MOH/Research & Technical Support
Ethical Application Status
Individual Clinical Trial Participant–level Data of Individual Participant Data (IPD) Sharing